Journal of the Korea Academia-Industrial cooperation Society (한국산학기술학회논문지)

The Korea Academia-Industrial cooperation Society (한국산학기술학회)
권호 표지
DOI QR코드

DOI QR Code

Down syndrome in women aged more than 35 Years positive detection rates

산전선별검사를 통한 35세이상 산모 다운증후군 양성률 비교 평가

  • Oh, Taek Min (Department of Biomedical Laboratory Science, Graduate School, Dankook University) ;
  • Kim, Ga-Yeon (Department of Dental Hygiene, Dankook University) ;
  • Lee, Young ki (Department of Biomedical Laboratory Science, Graduate School, Dankook University)
  • 오택민 (단국대학교 임상병리학과) ;
  • 김가연 (단국대학교 치위생학과) ;
  • 이영기 (단국대학교 임상병리학과)
  • Received : 2021.03.09
  • Accepted : 2021.06.04
  • Published : 2021.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

With the increasing age of motherhood in recent years, attributed to late marriages due to social or environmental factors, the Down's syndrome screening test using biochemical markers has become essential for pregnant women. The process of diagnosing Down's syndrome pregnancy in the high-risk group subjects involves chromosomal analysis, which is performed on samples obtained through invasive procedures such as chorionic biopsy or amniotic fluid. Thus, to reduce unnecessary invasive tests and lower the risk to mother and fetus, it is important to identify a screening test with low risk and high Down's syndrome detection rate. Recently, as the average age of mothers has increased, numerous inspection agencies have classified high-risk mothers as women over the age of 35 years. This study evaluated a total of 36,436 pregnant women aged between 17 to 46 years, and who requested prenatal screening at an inspection agency in Yongin in 2018. Test (13,690 people) Four tests were conducted by applying the time-resolved fluoroimmunoassay method using the direct sandwich and indirect sandwich technology, and the immunoassay method using the sandwich method. We aimed to confirm the difference in positivity rate with increasing age of the subjects. We believe that in future, data obtained from this study will be very useful for the prevention and treatment of Down's syndrome risk at varied inspection institutions, and for prospective mothers.

최근 사회적으로 결혼연령이 높아짐에 따라 고령산모가 증가하면서 생화학적 표지물질을 이용한 다운증후군 선별검사는 산모들에게 필수적인 검사가 되었다. 다운증후군 임신을 진단하는 과정은 선별검사에서 고위험군으로 보고 되면 융모막 융모생검이나 양수검사 같은 침습적 검사를 통해 염색체 분석을 하는 단계로 진행이 되는데 이러한 확진검사는 비용이 많이 들고 태아손실의 위험도가 높다. 따라서 위험도는 낮고 다운증후군 발견율이 높은 선별검사를 선택하여 불필요한 침습적 검사를 줄여 산모와 태아의 위험도를 낮추는 것이 중요하다. 본 연구는 2018년 용인의 임상검사기관에 산전선별검사를 의뢰한 17세부터 46세까지 총 36,436명을 대상으로 triple test(185명), quad test(3,629명), integrated test(18,932명), sequential test(13,690명) 4가지 검사를 direct sandwich, indirect sandwich 기술을 이용한 Time-resolved fluoroimmunoassay 방법과 sandwich 방법을 이용한 면역측정 방법을 사용하여 35세 미만과 35세 이상 산모의 다운증후군 위험도를 분석하여 산모 연령이 증가함에 따른 양성률의 차이를 확인하였다. 검사결과 전체 산모의 다운증후군 고위험군은 triple test 36명, quad test 408명, integrated tset 1,441명, sequential test 924명 이었다. 이중 35세미만 산모의 고위험군은 triple test 7명(3.8%), quad test 141명(3.9%), integrated tset 644명(3.4%), sequential test 430명(3.4%)이었고, 35세이상 산모의 고위험군은 29명(15.7%), 267명(7.4%), 797명(4.2%), 494명(3.6%)으로 나타나 35세이상 산모가 훨씬 높은 고위험군을 나타내었다. 임상에 있어서 35세 미만과 35세 이상 산모의 위험도 분석을 한 연구는 국내외에 거의 희박하므로 본 연구는 향후 국내외의 많은 검사기관들과 예비 산모들에게 다운증후군 위험의 예방과 치료를 위한 매우 유용한 기초 자료가 될 것으로 생각된다.

Keywords

References

  1. E. Jung, "Prenatal screening for Down syndrome", Korean Journal of Obstetrics & Gynecology, Vol.53, No.12, pp.1041-1046, 2010. DOI: https://doi.org/10.5468/kjog.2010.53.12.1041
  2. Y. D. Young, "The evaluation of integrated test as an antenatal screening test for down's syndrome in Korea", Laboratory Medicine Online, Vol.1, No.1, pp.10-18, 2011. DOI: https://doi.org/10.3343/lmo.2011.1.1.10
  3. N. J. Wald, A. Kennard, A. Hackshaw, A. Mcguire, "Antenatal screening for Down's syndrome", Journal of Medical Screening, Vol.4, No.4, 181-246, 1997. DOI: https://doi.org/10.1177%2F096914139700400402 https://doi.org/10.1177%2F096914139700400402
  4. H. S. Cuckle, N. J. Wald, R. Lindenbaum, "Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome", The Lancet, Vol.323, No.8383, pp.926-929,1984. DOI: https://doi.org/10.1016/S0140-6736(84)92389-4
  5. N. J. Wald, H. S. Cuckle, J. W. Densem, K. Nanchahal, Royston. P., Chard, T, "Maternal serum screening for Down's syndrome in early pregnancy", BMJ Vol.297, No.883-7, pp.1988. DOI: https://doi.org/10.1136/bmj.297.6653.883
  6. Wald, N. J, "Prenatal screening for Down's syndrome using inhibin-A as a serum marker", Prenatal Diagnosis: Published in Affiliation With the International Society for Prenatal Diagnosis, Vol.16, No.2, pp.143-153, 1996. DOI: https://doi.org/10.1002/(SICI)1097-0223(199602)16:2<143::AID-PD825>3.0.CO;2-F
  7. Cuckle, howars, Wald, N. J, Lindenbaum, richardh, "Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome", The Lancet, Vol.323, No.8383, pp. 926-929, 1984. DOI: https://doi.org/10.1016/S0140-6736(84)92389-4
  8. Van lith, J. M. M, "Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome", Prenatal diagnosis, Vol.12, No.10, pp.801-806, 1992. DOI: https://doi.org/10.1002/pd.1970121005
  9. Wald, N. J., Rish, Simon., Hackshaw, K. Allan, "Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies", Prenatal diagnosis, Vol.23, No.7, pp.588-592, 2003. DOI: https://doi.org/10.1002/pd.627
  10. Groome, P. nigel, evans, W. Lee, "Does measurement of inhibin have a clinical role", Annals of clinical biochemistry, Vol.37, No.4, pp.419-431, 2000. DOI: https://doi.org/10.1177%2F000456320003700401 https://doi.org/10.1177%2F000456320003700401
  11. Hussamy DJ, Herrera CL, Twickler DM, Mcintire DD, Dashe JS. "Number of Risk Factors in Down Syndrome Pregnancies" Am J Perinatol. Vol 36, pp.79-85, 2019 DOI: https://doi.org/10.1055/s-0038-1666974
  12. R. Bindra, Heath, V., Liao, A, Spencer, K., Nicolaides, KH, "One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15,030 pregnancies", Ultrasound Obstet Gynecol, Vol.20, pp.219-25, 2002. DOI: https://doi.org/10.1046/j.1469-0705.2002.00808.x
  13. Brizot, M. L, "Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy", BJOG: An International Journal of Obstetrics & Gynaecology, Vol.102, No.2, pp.127-132, 1995. DOI: https://doi.org/10.1111/j.1471-0528.1995.tb09065.x
  14. Alldred SK, Takwoingi Y, Guo B, Pennant M, Deeks JJ, Neilson JP, Alfirevic Z. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. "Cochrane Database of Systematic Reviews 2017" Issue 3. 2021. DOI: https://doi.org/10.1002/14651858.CD012600
  15. Wald, N. J. "First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS)", Journal of medical screening, Vol.10, No.2, pp.56-104, 2003. DOI: https://doi.org/10.1177%2F096914130301000202 https://doi.org/10.1177%2F096914130301000202
  16. Wapner, J. ronald, "First trimester screening: the BUN study. In: Seminars in perinatology", WB Saunders, p, pp.236-239, 2005. DOI: https://doi.org/10.1053/j.semperi.2005.05.013
  17. C. Y. Choi, et al, "DSCR 1-mediated TET 1 splicing regulates miR-124 expression to control adult hippocampal neurogenesis", The EMBO journal, Vol.38, No.14 pp.e101293, 2019 DOI https://doi.org/10.15252/embj.2018101293
  18. Hook, ernest B, "Rates of chromosome abnormalities at different maternal ages", Obstetrics and gynecology, Vol.8, No.3 pp.282-285, 1981.
  19. H. S. Cuckle, Wald, N. J, THOMPSON, S. G, "Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level", BJOG: An International Journal of Obstetrics & Gynaecology, Vol.94, No.5 pp.387-402, 1987. DOI: https://doi.org/10.1111/j.1471-0528.1987.tb03115.x
  20. Saller, N. devereux, Canick, A. jacob, "Maternal serum screening for fetal Down syndrome: clinical aspects", Clinical obstetrics and gynecology, 39.4: 783-792, 1996. https://doi.org/10.1097/00003081-199612000-00007
  21. N. J. Wald, H. C. Watt, Hackshaw, A. K, "Integrated screening for Down's syndrome based on tests performed during the first and second trimesters", New England Journal of Medicine, Vol.341, NO.7, pp.461-467, 1999. DOI: https://doi.org/10.1056/NEJM199908123410701
  22. Malone, D. fergal, "First-trimester sonographic screening for Down syndrome", Obstetrics & Gynecology, Vol.102, No.5 pp.1066-1079, 2003. DOI: https://doi.org/10.1016/j.obstetgynecol.2003.08.004
  23. Pandya, P. pranav , "Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation", BJOG: An International Journal of Obstetrics & Gynaecology, Vol.102 No.12, pp.957-962, 1995. DOI: https://doi.org/10.1111/j.1471-0528.1995.tb10902.x
  24. D. M. Strah, P. Maja, Gersak, Ksenija, "Risk assessment of trisomy 21 by maternal age and fetal nuchal translucency thickness in 7096 unselected pregnancies in Slovenia", Journal of perinatal medicine, Vol.36, No.2, pp.145-150, 2008. https://doi.org/10.1515/JPM.2008.015
  25. ACOG educational bulletin. Adult manifestation of childhood sexual abuse. 2000. number 259, Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet, Vol.74, pp.311-20, 2001. https://doi.org/10.1016/S0020-7292(01)00491-X
  26. T. S. martin, "Responding to parental concerns after a prenatal diagnosis of trisomy 21", Journal of developmental and behavioral pediatrics, Vol.18, No.1, pp.42-46, 1997. DOI: https://doi.org/10.1515/JPM.2008.015
  27. Rose, Nancy C. MD, Kaimal, Anjali J. MD, MAS, Dugoff, Lorraine MD, Norton, Mary E. MD. "Committee on Practice Bulletins-Obstetrics Committee on Genetics Society for Maternal-Fetal Medicine Screening for Fetal Chromosomal Abnormalitie"American College of Obstetricians and Gynecologists. Vol.136, pp48-69, 2020. DOI: https://doi.org/10.1097/AOG.0000000000004084